Context: Polycystic ovary syndrome (PCOS) is a heterogeneous disease with many different aspects, including hyperandrogenism and metabolic disturbances. Clinical phenotypes show different patterns of steroid hormones that have been investigated to some extent.
P
olycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder, affecting up to 15% of women of reproductive age (1) . The diverse spectrum of phenotypes includes metabolic and reproductive features and still, no universally accepted clinical definition for PCOS exists. According to the Rotterdam ESHRE consensus of 2004, two of three clinical features are needed for the diagnosis, eg, hyperandrogenism, oligo-or amenorrhea, and polycystic ovaries determined by ultrasound (1) . Moreover, additional symptoms like insulin resistance and abnormal glucose metabolism and obesity are very frequent in PCOS patients. Long-term consequences of PCOS range from metabolic dysfunction to increased cardiovascular events (2, 3) . PCOS women with androgen excess are at higher risk of insulin resistance, liver disease, and subclinical atherosclerosis compared to PCOS patients with normal androgen levels (4 -6) . Clinical phenotypes of PCOS patients show different patterns of steroid hormones that have been investigated to some extent (7) . However, there is still no clear consensus which androgens should be measured and which analytical technique should be used for quantification (8) . Due to a lack of sensitivity and specificity of direct immunoassays and the very low serum concentrations of steroid hormones in children and women, The Endocrine Society recommends avoiding immunoassays for steroid hormone quantifications (9) . Instead, the more precise mass spectrometry (MS) steroid assays should be used. It is assumed that MS based techniques like liquid chromatography/mass spectrometry (LC-MS) or gas chromatography/mass spectrometry (GC-MS) will replace immunoassays and will become a mandatory submission requirement for high-quality scientific papers by 2015 (10) .
At present, testosterone is the most common measurement in routine clinical practice for the investigation of female hyperandrogenism (11) . However, a recent study by O'Reilly et al showed that androgen excess might be missed if only testosterone is measured, since PCOS patients with high androstenedione, but normal testosterone are at high risk for metabolic disease (12) . Androgens like testosterone can be secreted from the ovaries and the adrenal glands, but can also be generated from precursors in adipose or peripheral tissues. Steroid hormones like androstenedione or testosterone can themselves be further metabolized to other steroids, involving the activity of many different genes and enzymes. One key enzyme is 5␣-reductase, which is responsible for the conversion of testosterone to its metabolite dihydrotestosterone (DHT) and of tetrahydrocortisol (THF) to 5␣-tetrahydrocortisol (5␣-THF).
Since PCOS patients with androgen excess are at high risk for metabolic consequences like liver diseases and insulin resistance, it is important to identify those patients who have abnormal androgen constellations. We hypothesize that the diagnosis of women with metabolic complications in PCOS patients should not be based on single steroid hormone measurements like testosterone or free testosterone, but should comprise the quantification of several steroid hormones and a further analysis of the relationship of these hormones to each other. We therefore hypothesize that the comeasurement of testosterone and DHT is important for the diagnosis of PCOS and that an abnormal ratio of total testosterone to DHT (TT/DHT ratio) contributes to the metabolic deterioration in PCOS patients. We therefore carried out a detailed analysis of the TT/DHT ratio in a large cohort of PCOS patients according to the Rotterdam criteria in comparison with a group of body mass index (BMI)-matched healthy controls, based on high-standard MS results.
Materials and Methods

Study population
Two hundred seventy five premenopausal PCOS patients were included in this study. All PCOS patients fulfilled the Rotterdam ESHRE 2004 criteria (1). Other disorders with a similar clinical presentation, such as congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors or hyperprolactinemia were excluded. Therefore, specific laboratory analysis [cortisol, prolactin, 17␣-hydroxyprogesterone, adrenocorticotropic hormone (ACTH)] were performed. Clinical and/or biochemical hyperandrogenism was assessed by the presence of acne, hirsutism (Ferriman-Gallwey score Ն 8), alopecia, and/or elevated androgen levels in serum. Hirsutism was quantified with the modified Ferriman-Gallwey score. Polycystic ovarian morphology was examined by ultrasound, as described previously (7) . Oligo-ovulation and/or anovulation were defined by the presence of oligomenorrhea or amenorrhea.
Additionally, 35 BMI-matched, premenopausal, healthy controls were included in this study. A normative cohort of 38 healthy, premenopausal women, age-matched with the PCOS cohort and enrolled at the University of South Manchester, United Kingdom, was used to validate the TT/DHT ratio of the control group. Exclusion criteria for patients as well as controls and the normative cohort were systemic illnesses, pregnancy, previous intake of antiandrogenic drugs, previous intake of any drugs known to affect endocrine parameters, serum lipid profile, carbohydrate metabolism or hepatic P450 enzymes, or intake of oral contraceptives within 3 months before entering the study. The study protocol was approved by the Ethics Committee of the Medical University of Graz. All participants gave written informed consent.
Metabolic characterization
Standard anthropometric data, such as weight, height, waist circumference (WC), hip circumference (HC) were obtained. Additionally, systolic and diastolic blood pressure (BP) were measured. The BMI was calculated by dividing weight in kilograms by height in square meters. Normal weight was defined as BMI Ͻ 25 kg/m 2 and obesity as BMI Ն 30 kg/m 2 . All participants underwent an overnight fast before blood samples for basal hor-mone serum levels were obtained. Furthermore, a fasting 75 g oral glucose tolerance test (OGTT) was performed and blood samples were collected after 30, 60, and 120 min for the determination of glucose and insulin levels. An impaired glucose tolerance (IGT) or prediabetes was identified by glucose levels between 140 and 199 mg/dL after 2 h, as defined by the American Diabetes Association (ADA) (13) . The area under the curve (AUC) of insulin and glucose was calculated by the trapezoidal method with normalization to baseline values. Insulin resistance was determined by values above 2.5 in the homeostatic model assessment-insulin resistance (HOMA-IR). HOMA-IR was calculated by the product of fasting insulin (IU/mL) and fasting glucose levels (mg/dL), divided by 405 (14) . The quantitative insulin sensitivity check index (QUICKI) was calculated as 1/(log(fasting insulin U/mL) ϩ log(fasting glucose mg/dL) (15) . A metabolic syndrome was diagnosed at the presence of at least three of the following criteria: raised fasting glucose levels (Ͼ 110 mg/dL) or already prevalent type 2 diabetes mellitus, triglyceride levels Ͼ 150 mg/dL, high-density lipoprotein (HDL) cholesterol Ͻ 50 mg/dL, a WC above 88 cm, and raised BP, such as systolic values Ͼ 130 mm Hg and diastolic levels Ͼ 85 mm Hg (16) .
Mass spectrometry
Concentrations of serum total testosterone, total DHT, androstenedione, and dehydroepiandrosterone (DHEA) were measured from frozen aliquots using an established routine method for liquid chromatography/mass spectrometry (LC-MS/MS) in the Department of Clinical Chemistry at the University Hospital of South Manchester, Manchester, UK. Frozen samples were sent to South Manchester on dry ice within 24 h. In brief, samples were extracted using an automated on-line solid phase extraction on a C18 cartridge by an On-line SPE Manager (OSM) (Waters). Cartridges were initially conditioned with methanol and equilibrated with water. After sample loading, a 35% methanolic cartridge wash was utilized. Compounds were eluted from the cartridge using the first 0.5 min of the mobile phase gradient.
Chromatography was performed using a 50 ϫ 2.1 mm Acquity HSS SB column (Waters) with a 3 min gradient of 50 -70% methanolic mobile phase (0.45 mL/min) containing 0.05% formic acid. The time from injection to injection was 6.5 min.
Analytes were measured using a TQ-S tandem mass spectrometer (Waters) with the following quantifier and (qualifier) transitions: testosterone 289. Chromatographic separation was achieved between all four androgens with a run time of 6.2 min per sample. Calibration lines were linear (r 2 Ͼ 0.99) to at least 14.42 ng/mL for testosterone, androstenedione, and DHEA and 1.45 ng/mL for DHT. The lower limit of quantitation was 0.02 ng/mL for testosterone, androstenedione, and DHT, and 0.28 ng/mL for DHEA. The between assay imprecision was good with CVs of Ͻ 6% for testosterone, Ͻ 10% for DHT, Ͻ 7% for androstenedione, and Ͻ 10% for DHEA at concentrations of 0.17, 0.06, 0.48, and 0.95 ng/mL, respectively.
Immunoassays
The sex hormone binding globulin (SHBG) was measured using the luminescence immunoassay (Roche) with intra-and interassay CVs of 1.3% and 2.1%. Triglycerides, cholesterol, HDL, and low-density lipoprotein (LDL) were determined using Modular Analytics SWA (Roche) with intra-and interassay CVs Ͻ 10%. Photometrical assays were used for measuring Albumin (Roche) and ELISAs were used for assessing concentrations of dehydroepiandrosterone sulfate (DHEAS) (LDN Labor Diagnostika Nord GmbH) and 17alpha-hydroxyprogesterone (DiaMetra, Biovendor) with intra-and interassay CVs Ͻ 10%.
Calculations
Free testosterone and free DHT were calculated according to Vermeulen et al (17) . The free androgen index (FAI) was calculated as total testosterone (nmol/L) ϫ 100/SHBG (nmol/L). TT/ DHT ratio was calculated as total testosterone divided by total DHT levels.
Statistics
To evaluate the distribution of data, descriptive statistics and Kolmogorov-Smirnov tests were performed. The differences between women with PCOS and controls were analyzed with the Mann-Whitney-U test for non-normally distributed independent samples. Univariate associations were assessed by the twotailed Spearman rank correlation test, using BMI and age as covariates. Binary logistic regression analyses were carried out to determine the associations of insulin resistance (yes/no; defined as HOMA-IR Ͼ 2.5), metabolic syndrome (yes/no), and IGT (yes/no) with the TT/DHT ratio as well as age and BMI as covariates. Receiver operating characteristics (ROC) curves of the TT/DHT ratio were constructed to determine the optimal cutoff point, estimated by the Youden index (18), for the diagnosis of PCOS, metabolic syndrome, IGT, and insulin resistance assessed by HOMA-IR. Data are presented as median with interquartile range (IQR) unless otherwise stated. All analyses were performed in SPSS 19.0 (SPSS Inc) with P values Ͻ.05 being significant.
Results
Clinical and metabolic characteristics of PCOS patients and healthy controls are presented in Table 1 somewhat older than PCOS patients, however, no study participant was in menopause or premenopause, and age and BMI were considered as covariate in all analyses. Statistically significant differences between PCOS patients and healthy controls were found. Most serum steroid hormone levels were significantly higher in PCOS patients, eg, testosterone (P Ͻ .001), androstenedione (P Ͻ .001), DHEA (P Ͻ .001), and DHEAS (P Ͻ .001). No difference in serum levels was found for DHT (P ϭ .072). Calculated levels of free testosterone and free DHT were significantly higher in PCOS patients (P Ͻ .001 and P Ͻ .001).
In the normative cohort of 38 healthy women (median age: 29; IQR: 25-32. were within the same range as the control group. The TT/ DHT ratio was significantly higher in PCOS patients (P Ͻ .001).
In PCOS patients alone, women with metabolic syndrome showed higher levels of calculated free testosterone (P ϭ .047) and a higher TT/DHT ratio (P Ͻ .001), but significantly lower levels of free DHT (P ϭ .001) and total DHT (P Ͻ .001). No difference was found for DHEA, DHEAS, androstenedione or testosterone between patients with or without the metabolic syndrome. Regarding the OGTT, PCOS patients with IGT had significantly higher free testosterone levels (P ϭ .017) and a higher TT/DHT ratio (P Ͻ .001), whereas DHT was significantly lower (P Ͻ .001). Similar results were found for patients with insulin resistance according to the HOMA-IR. Insulin resistant PCOS patients showed significantly higher free testosterone levels (P Ͻ .001) and a higher TT/DHT ratio (P Ͻ .001), but lower DHT levels (P Ͻ .001). Furthermore, PCOS patients with hypertension, defined as systolic BP values Ͼ 140 mm HG and diastolic values Ͼ 90 mm HG, showed a significantly higher TT/ DHT ratio (P ϭ .001).
To determine the significant independent association of metabolic syndrome, IGT or HOMA-IR and TT/DHT ratio in PCOS patients, binary logistic regression analyses were performed, including age, BMI, and TT/DHT ratio as independent variables. Age (P ϭ .035), BMI (P Ͻ .001), and TT/DHT ratio (P ϭ .024) were independent predictors for the presence of metabolic syndrome. Similar results were found using IGT as a dependent variable (P ϭ .011, P ϭ .003, P ϭ .005, respectively). Binary logistic regression analysis with age, BMI, and total testosterone instead of the TT/DHT as independent variables showed no significant results for total testosterone as an independent predictor of metabolic syndrome (P ϭ .592), IGT (P ϭ .972), and insulin resistance (P ϭ .691). In a multivariate regression analysis controlled for age and BMI, DHT was an independent predictor for impaired glucose tolerance (P ϭ .045), but not for metabolic syndrome (P ϭ .054) or insulin resistance (P ϭ .057).
Comparing overweight and obese (BMI Ն 25 kg/m 2 ) and nonobese PCOS patients (BMI Ͻ 25 kg/m 2 ), we found significantly higher serum levels of DHT in nonobese patients (P Ͻ .001), but no difference was found for testosterone (P ϭ .093). Regarding the TT/DHT ratio, a signif- Differences between PCOS patients and healthy controls were analyzed with Mann-Whitney U test for non-normally distributed independent samples. Values are expressed as median (25th-75th interquartile ranges). P valuesϽ.05 are considered to be significant.
icantly higher ratio was found in the group of overweight and obese PCOS patients (P Ͻ .001) ( Table 2 ). The ROC curve analyses revealed that the best cutoff value for the TT/DHT ratio to diagnose PCOS was 4.37 (sensitivity 50.5%, specificity 82.9%, and AUC 0.694) (Figure 1) . In PCOS patients, the cutoff value for the TT/ DHT ratio for metabolic syndrome calculated via ROC curve analyses was 4.32 (sensitivity 86.0%, specificity 54.9%, and AUC 0.768), for IGT 3.97 (sensitivity 79.7%, specificity 50.0%, and AUC 0.678) and for insulin resistance assessed by HOMA-IR 4.20 (sensitivity 77.7%, specificity 56.4%, and AUC 0.711).
In age and BMI adjusted Spearman correlation analysis in PCOS patients, the TT/DHT ratio was signifi- cantly correlated with waist circumference, weight, adverse parameters of glucose metabolism, adverse lipid and liver parameters, and higher hormone levels (Table  3) . Negative correlations of TT/DHT ratio were found for DHEAS (r ϭ Ϫ0.282, P Ͻ .001), DHEA (r ϭ Ϫ0.173, P ϭ .004), and free DHT (r ϭ Ϫ0.407, P Ͻ .001). No correlations were found for the Ferriman-Gallwey score, LH, antimullerian hormone (AMH), and progesterone or when using testosterone alone instead of the TT/DHT ratio (data not shown).
Discussion
This is the first study to show a detailed assessment of the TT/DHT ratio in a large cohort of well-characterized PCOS patients, revealing a strong link with adverse hormonal, anthropometric, and metabolic parameters. Our findings are based on a comprehensive steroid hormone measurement by liquid chromatography/mass spectrometry, carried out in an experienced center for steroid hormone measurement (19 -21) . Because of their high specificity and sensitivity, mass spectrometric steroid hormone assays are regarded as the method of choice for the quantifications of hormone levels and evaluation of androgen excess in women (22) . Polycystic ovary syndrome is a heterogeneous disease with many different phenotypes and metabolic aspects. Still, there is no clear consent about the diagnosis of PCOS, but hyperandrogenism is regarded as one key factor. Therefore, androgen excess should be evaluated in all women suspected of having PCOS (23) . Previous studies suggested that for the diagnosis of hyperandrogenism steroid hormones should not be regarded as single values, but should be considered in relationship to each other (7, 12) . Serum testosterone is the most common used marker for biochemical androgen excess (11) , that can be produced either directly by the ovaries or generated by the metabolism of its precursor androstenedione in adipose or peripheral tissues (24) . Testosterone itself can further be converted to DHT by the activity of the enzyme 5␣-reductase, which is also responsible for the conversion of tetrahydrocortisol (THF) to 5␣-tetrahydrocortisol (5␣-THF). Previous studies reported different results concerning the activity level of the 5␣-reductase in PCOS patients, maybe due to different techniques for the assessment of the enzyme activity and/or different sample sizes. However, in the present study we focused not on enzyme activities but on more systemic effects of an impaired hormonal balance. Therefore, we have chosen the ratio of testosterone to its as more potent considered metabolite DHT for further investigation.
All 275 PCOS patients included in our study were premenopausal at reproductive age and met the recommended ESHRE Rotterdam criteria of 2004. In contrast to the 35 BMI-matched, premenopausal group of healthy controls, PCOS patients showed a significantly higher TT/ DHT ratio. We took a deeper look on the effect of this higher TT/DHT ratio in PCOS patients and assessed the correlation of this ratio with various hormonal, anthropometric and metabolic parameters. In PCOS patients alone, we found a significantly higher TT/DHT ratio in obese patients (BMI Ն 30 kg/m 2 ). We also found significantly lower serum levels of DHT in obese PCOS patients, confirming previous studies reporting lower DHT values in obese children and obese adolescents with PCOS (25, 26) . We could further show that a high TT/DHT ratio is an independent predictor for the presence of metabolic syndrome in PCOS patients. We assessed a higher TT/ DHT in PCOS patients with IGT, insulin resistance, obesity or metabolic syndrome. The adverse effect of the TT/ DHT ratio on the glucose metabolism was evidenced by statistically significant associations with various parameters of this metabolism, like higher fasting glucose levels and higher glucose levels after 30, 60, and 120 min in the OGTT, as well as higher fasting glucose, QUICKI, HOMA, and higher insulin and glucose response curves.
In line with this, we found significant associations of a high TT/DHT ratio with numerous other adverse metabolic factors, like liver (AST, ALT, cholesterol, triglycerides) and hormonal parameters (androstenedione, free testosterone, free androgen index, DHEAS, DHEA, free DHT).
The high sensitivity and specificity of the TT/DHT ratio detected in the ROC curve analysis indicate that the TT/ DHT ratio might be a useful marker for the diagnosis of PCOS and for the prediction of metabolic syndrome, IGT, and insulin resistance in PCOS women. We further assessed significantly lower levels of DHEA and DHEAS associated with a higher TT/DHT ratio, which are both abundant steroids almost exclusively derived from the adrenal cortex (98%). Another previous study by Stener-Victorin et al assessed various sex steroid hormones and glucoronidated androgen metabolites in PCOS patients by liquid chromatography/tandem mass spectrometry (27) . They did not find any difference in PCOS patients and healthy controls regarding the TT/ DHT ratio. However, the number of PCOS patients included in the study cohort was smaller than our study group, which could lead to different results, and they did not assess any correlations with metabolic parameters.
One strength of our study is the large number of wellcharacterized PCOS patients in our cohort. We used a validated mass spectrometry method for the quantification of four important steroids and measurements were carried out in a well experienced center for steroid research and diagnostics. The concise control group comprised healthy, BMI-matched controls, based on strong exclusion criteria. Though this control group was relatively small, we included another normative control group, which was age-matched with the control group, showing analogous results. Our main focus was put on the metabolic effects of the TT/DHT ratio in PCOS patients, and therefore we emphasize having a BMI-matched control groups, based on the distinct correlation of BMI and metabolic parameters. Although our control group was somewhat older than the group of PCOS patients, all women were premenopausal, and the group of PCOS patients still showed worse metabolic parameters despite their younger age. To exclude a potential bias, age and BMI were considered as covariates in all analyses. In conclusion, these data provide evidence for a strong link between a high TT/DHT ratio and an adverse metabolic phenotype in PCOS patients. This correlation was only found in PCOS patients, suggesting the TT/DHT ratio is a new biomarker for an adverse metabolic phenotype in PCOS patients. Nevertheless, future studies and larger trials are needed for the evaluation of results.
